RadhakrishnanRamchandrenMD

Hematologic Oncology

Professor Department of Medicine University of Tennessee Knoxville Division Chief Hematology Oncology

Dr. Ramchandren is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a board certified hematologist oncologist specializing in the care of patients with lymphoma with a clinical and research interest in Hodgkin lymphoma. In particular I am interested in novel therapies for treatment of lymphoma and am involved in numerous clinical trials.

Ascension Providence/MSUCHMFellowship, Hematology and Medical Oncology, 2005 - 2008
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 2001 - 2004
Ross University School of MedicineClass of 2001

leukemia lymphoma society man of the year candidate leukemia lymphoma society of Michigan, 2014

PubMed

8 citations
Cardiac Amyloid Detection by PET/CT Imaging of Iodine (I) Evuzamitide (I-p5+14): A Phase 1/2 Study.
Jonathan S Wall, Emily B Martin, Ronald Lands, Radhakrishnan Ramchandren, Alan Stuckey
JACC. Cardiovascular Imaging. 2023-11-01
10 citations
The iRregimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna
Eclinicalmedicine. 2023-02-01
Editorial: Advances in the treatment of Hodgkin lymphoma.
Matthew Mei, Guilherme Perini, Radhakrishnan Ramchandren
Frontiers in Oncology. 2023-01-01

Journal Articles

Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin Lymphoma
Patrick B. Johnston, Radhakrishnan Ramchandren, Lauren C. Pinter-Brown, BioMed Central

Abstracts/Posters

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124I-p5+14, for Imaging Systemic Amyloidosis
Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

ASCO 2018: Dr. Radhakrishnan Ramchandren on the North American Results of the Frontline AAVD StudyJune 2018

Nivolumab in Newly Diagnosed Advanced cHLSeptember 20th, 2019
Nivolumab for Newly Diagnosed AdvancedApril 8th, 2019
OncLive® Presents the Latest State of the Science Summit™ on Hematologic MalignanciesSeptember 5th, 2018
Join now to see all